Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016
- Pages: 767
- Published: November 2016
- Report Code: GMDHC8731IDB
Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016’, provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
AbbVie Inc
Acetylon Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Altor BioScience Corp
Amgen Inc
Aprea AB
Aptevo Therapeutics Inc
Arno Therapeutics Inc
ArQule Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
Baliopharm AG
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Biogen Inc
Bionomics Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
Cellectis SA
Cellular Biomedicine Group Inc
Coherus BioSciences Inc
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GeneaMed Ltd
Genentech Inc
Genor BioPharma Co Ltd
Gilead Sciences Inc
Grupo Ferrer Internacional SA
Hutchison MediPharma Ltd
Hybrigenics SA
Igenica Biotherapeutics Inc
Immatics Biotechnologies GmbH
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Inflection Biosciences Ltd
Innate Pharma SA
Innovent Biologics Inc
Johnson & Johnson
Juno Therapeutics Inc
Kancera AB
Karyopharm Therapeutics Inc
Kite Pharma Inc
Les Laboratoires Servier SAS
LFB SA
Lymphocyte Activation Technologies SA
Medicenna Therapeutics Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MorphoSys AG
NantKwest Inc
Nordic Nanovector ASA
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co Ltd
Panacea Biotec Ltd
PEP-Therapy SAS
Pfizer Inc
Pharmacyclics Inc
PIQUR Therapeutics AG
Portola Pharmaceuticals Inc
Redx Pharma Plc
Respiratorius AB
Revitope Oncology, Inc.
Rhizen Pharmaceuticals SA
Sandoz International GmbH
Sanofi
Selvita SA
Simcere Pharmaceutical Group
Sorrento Therapeutics Inc
Supratek Pharma Inc
Takeda Pharmaceutical Company Ltd
Targazyme Inc
TG Therapeutics Inc
The International Biotechnology Center (IBC) Generium
Theravectys SA
Tolero Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
Trillium Therapeutics Inc
United BioPharma, Inc.
Unum Therapeutics Inc
Verastem Inc
VioQuest Pharmaceuticals Inc
Viralytics Ltd
Xencor Inc
ZIOPHARM Oncology Inc
Zymeworks Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.